Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 PSMA-617 in Metastatic Clear Cell Renal Carcinoma
NCT06959433Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- May 2026
- Primary completion
- Feb 2028
- Sponsor
- Ankara University
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Conditions
- renal cell carcinoma (RCC)
01
Overview
Phase 3, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in renal cell carcinoma (RCC), sponsored by Ankara University. Primary endpoint: Toxicity Analysis. Planned start May 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Lu-PSMA treatment arm
Patients receiving Lu-177 PSMA treatment for metastatic RCC
03
Who it enrols
Adults with metastatic renal cell carcinoma who have progressed after at least 2 lines of systemic therapy, have an ECOG performance status of 0-2, a life expectancy of at least 3 years, and no prior radionuclide therapy or secondary malignancies.
04
Endpoints
Primary
Toxicity Analysis
Secondary
Efficacy Analysis
Beyond the preview
Go deeper on NCT06959433.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959433.